Business Wire

NY-EMPIRE-STATE-REALTY

30.1.2024 21:15:26 CET | Business Wire | Press release

Share
‘World’s Most Romantic Building:’ Empire State Building Celebrates Valentine’s Day with NYC's Most Romantic Date Experience, Engagement Package, and Film Screenings

Celebrate the most romantic day of the year at the “World’s Most Romantic Building.” The Empire State Building (ESB) – the number one attraction in the U.S. by Tripadvisor travelers for two consecutive years – announced today that it will host themed movie screenings; offer an over-the-top, bucket list Valentine’s Day date for one lucky couple; and provide a special engagement package for couples who plan to tie the knot this February.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130140269/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

‘World’s Most Romantic Building:’ Empire State Building Celebrates Valentine’s Day with NYC's Most Romantic Date Experience, Engagement Package, and Film Screenings (Photo: Business Wire)

  • Empire for Two – This year, one lucky couple can book the Empire State Building’s first ever private Valentine’s Day dining experience, that for a $10k price tag gives them access to the entire 86th Floor Observatory all to themselves, as well as a three-course dinner with wine pairing high atop the exclusive 102nd Floor, that is also closed for the entirety of the date. Curated and prepared by the head chef at STATE Grill and Bar – the Empire State Building’s signature restaurant on ground level – dishes include options like lump crab with caviar, porcini crusted filet mignon, and a decadent chocolate cake, accompanied by a live musician and themed decor. Before dinner, the couple will embark on a private tour of the Empire State Building with Champagne. The lavish Empire for Two ticket package is available for Feb. 14 at 8:30 p.m. and must be reserved by Feb. 12.
  • “As IF!” – Gather your girlfriends this Galentine’s Day for a one-time screening of the quotable comedy “Clueless” on the Empire State Building Observatory’s 80th Floor on Feb. 13. Fans will enjoy drinks and snacks from Culture POP, Dylan’s Candy Bar, and Rob’s Backstage Popcorn included with their ticket. Mixologists will shake up complimentary espresso martinis – courtesy of the newly opened, 23,000 square foot Starbucks Reserve® located at the base of the building – for guests to sip on with the movie before they take in the views from the 86th and 102nd Floor Observatories.
  • “It’s a Sign” – Channel the romance of “Sleepless in Seattle” – the classic ‘90s love story that features scenes filmed at the “World’s Most Romantic Building” – in a special screening on Feb 14. Guests will enjoy the film screening on the building’s 80th Floor with complimentary drinks and snacks from Culture POP, Dylan’s Candy Bar, Rob’s Backstage Popcorn included with their ticket. In a nod to their deep Seattle heritage, Starbucks Reserve® will serve complimentary espresso martinis to guests before they recreate the movie magic on the 86th and 102nd Floor Observatories.
  • Happily Ever Empire – Toast to forever with ESB’s exclusive engagement experience this February. The Happily Ever Empire package includes an exclusive guided tour of the Observatory Experience; a private, roped-off corner of the 86th Floor Observatory to pop the question; and a bottle of Champagne to toast to your “yes!”
  • Love Lights – On Feb. 14, the Empire State Building’s world-famous tower lights will shine in a pink heartbeat in its annual Valentine’s Day gift to New York City. Text CONNECT to 274-16 to receive real-time information about the Empire State Building’s tower lights.

“There is no better backdrop than the Empire State Building’s unparalleled views as you celebrate love this Valentine’s Day,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “We are excited to offer the exclusive opportunity for one couple to have our iconic Observatory all to themselves in New York City’s most romantic date.”

The Empire State Building Observatory Experience recently underwent a $165 million reimagination that features an interactive museum with nine galleries, brand-new bespoke Observatory host uniforms, and iconic Observatories on the 86th and 102nd Floors.

Hi-res imagery can be downloaded here. More information about the Empire State Building and tickets can be found online.

About the Empire State Building

The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the US for the second year in a row in Tripadvisor’s 2023 Travelers’ Choice Awards: Best of the Best, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

Source: Empire State Realty Trust, Inc.
Category: Observatory

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130140269/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye